Incanthera PLC Result of AGM (8221S)

TIDMINC

RNS Number : 8221S

Incanthera PLC

08 November 2023

8 November 2023

Incanthera plc

("Incanthera" or the "Company")

Result of AGM 2023

Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed.

The Company would like to thank all Shareholders who returned their Proxy form and attended in person.

For further enquiries:

 
Incanthera plc 
 www.incanthera.com 
 
 Tim McCarthy, Chairman 
 tim.mccarthy@incanthera.com                +44 (0) 7831 675747 
 
 Simon Ward, Chief Executive Officer 
 simon.ward@incanthera.com                  +44 (0) 7747 625506 
 
 Suzanne Brocks, Head of Communications 
 suzanne.brocks@incanthera.com              +44 (0) 7776 234600 
 
Aquis Exchange Corporate Adviser: 
 Cairn Financial Advisers LLP 
 Jo Turner / Liam Murray                   +44 (0) 20 7213 0880 
 
Broker: 
 Stanford Capital Partners Ltd 
 Patrick Claridge / John Howes / 
 Bob Pountney                              +44 (0) 20 3815 8880

Notes to Editors

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions.

The Company's current focus is a range of dermatological applications utilising its unique formulation and delivery technologies to meet cosmetic and clinically unmet needs. This range will include the Company's potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. The Company is currently focussed upon delivering this range to a commercial partner.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: www.incanthera.com

@incantheraplc

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXMZMGMFRZGFZM

(END) Dow Jones Newswires

November 08, 2023 08:20 ET (13:20 GMT)

Incanthera (AQSE:INC)
過去株価チャート
から 11 2024 まで 12 2024